AUTHORS
Emily K Phillips, MD, Thomas Pfeiffer, MD2, Evelyn Schmidt3, Michelle Becker-Hapak4, Mark Foster5, Joseph Rueve6, Yoojin Ahn7, Sushanth Pureti8, Patrick Pence9, Manikanda Raja Keerthi Raja10, Rachel Elizabeth Granberg, MD, MPH11, Clare Zimmerman12, Amanda Cashen, MD13, Jeffrey Bednarski, MD, PhD14, Jennifer A. Foltz, PhD15, Todd Fehniger, MD, PhD16
AFFILIATIONS
1 Washington University School of Medicine, Saint Louis, Missouri, United States
2 Washington University School of Medicine, Saint Louis, Missouri, United States
3 Washington University School of Medicine, Saint Louis, Missouri, United States
4 Washington University School of Medicine, Saint Louis, Missouri, United States
5 Washington University School of Medicine, Saint Louis, Missouri, United States
6 Washington University School of Medicine, Saint Louis, Missouri, United States
7 Washington University School of Medicine, Saint Louis, Missouri, United States
8 Washington University School of Medicine, Saint Louis, Missouri, United States
9 Washington University School of Medicine, Saint Louis, Missouri, United States
10 Washington University School of Medicine, Saint Louis, Missouri, United States
11 Washington University School of Medicine, Saint Louis, Missouri, United States
12 Washington University School of Medicine, Saint Louis, Missouri, United States
13 Washington University School of Medicine, Saint Louis, Missouri, United States
14 Washington University School of Medicine, Saint Louis, Missouri, United States
15 Washington University School of Medicine, Saint Louis, Missouri, United States
16 Washington University School of Medicine, Saint Louis, Missouri, United States
ABSTRACT
Although 70% of pediatric patients with de novo acute myeloid leukemia (AML) survive, the prognosis is poor in patients who have relapsed or refractory (rel/ref) AML. Despite aggressive chemotherapy and allogeneic hematopoietic cell transplant (allo-HCT), over half of patients will die of AML. Thus, new approaches are necessary to induce prolonged remissions in these patients. Conventional NK (cNK) cells stimulated with Interleukin (IL)-12, IL-15, and IL-18 differentiate into memory-like (ML NK) cells which show enhanced attack against AML. We hypothesized that donor ML NK cells could induce remission in high-risk pediatric patients who have relapsed after allo-HCT. We previously reported the first 8 patients treated on a phase 1 clinical trial of HCT-donor memory-like NK cells, which demonstrated ML NK cell expansion and persistence (Blood, 2022; NCT01898793). Here, we report the full clinical trial results (n=18) with expanded correlative science.
Pediatric/young adult (YA) patients who relapsed after allo-HCT (n=18, median age 8; range 1-27 years) were treated between 2018-2023. 7 patients had 2 prior allo-HCTs. All patients had active AML, with median 35% (range 0.7-95%) bone marrow blasts; 1 patient had only extramedullary disease. One patient had T-ALL at the time of relapse and was excluded from efficacy analysis. Treatment was fludarabine, cytarabine, and GCSF (FLAG) salvage therapy as lymphodepletion, and 2 weeks later a donor lymphocyte infusion (DLI) on day -1 and ML NK infusion on day 0, both from their prior allo-HCT donor.
ML NK therapy was safe and well tolerated. Mild (grade 1 or 2) CRS was attributed to study therapy in 2 patients. No patients experienced ICANS. At day 28, complete remission (CR) was observed in 7/17 (41%) patients, with MRD negative (n=3) and MRD <0.1% (n=4). Non-responder (NR, 10/17, 59%) patients included stable disease in 1/17 (6%) or progressive disease in 9/17 (53%). Overall survival at 1 year was 57.1% for CRs and 10% for NRs. One patient is alive without AML or subsequent therapies 7.5 years after study therapy.
Correlative immunology focused on discovery of differences in NK cells between CR and NR. By flow, NK cells expanded between days 7 (median CR: 13.8, range: 0.7-36.6 c/µL; median NR: 18.4, range: 0-48.3 c/µL) and 28 (median CR: 85.7, range: 5.23-156.2 c/µL; median NR: 39.8, range 15.3-124.5 c/µL). The peak expansion through day 28 was not significantly different in patients with CR (median 5.8-fold, range: 0.5-183.5) and NR (median 2.3-fold, range: 1.1-15.1). CITE-seq was performed on 17 patients (7 CR, 10 NR): donor NK pre- and post-activation and 2-4 weeks post-infusion. Enriched ML (eML) NK cells have unique epigenetic and single cell transcriptional programs from conventional NK (cNK) cells, representing the genuine ML NK cell population (Foltz/Tran et al, Sci Immunol, 2024). eML were detectable in HCT-donor NK cells without cytokine activation at low levels (mean 1.27%), which increased to an average of 29.2% at day 14 post NK cell-infusion. Despite similar overall day 14 frequency, persistence of eMLs at day 28 was sustained in CR patients but significantly reduced in NRs (p. adj=0.005), suggesting that eML persistence is associated with clinical response. Spectral flow analysis was completed on day 14 (6 CR, 8 NR) and on day 28 (5 CR, 5 NR) for comprehensive NK cell immunophenotyping. There was significantly higher TIGIT expression on NK cells on day 14 (p=.0055) and day 28 (p=.0076) in NRs compared to CRs. NR’s ML NK cells had an increased frequency of CD8a (32%) compared to CR (16%, p=0.04), as well as increased expression of the inhibitory receptor NKG2A (p=.029). CITE-seq at day 28 also showed increased frequency of CD4+ T cells (p.adj=0.004), monocytes (p.adj=0.05), and dendritic cells (p.adj=0.009) in patients with CR, compared to NR.
In summary, a phase 1 clinical trial revealed a 41% CR rate when FLAG, DLI, and ML NK cells are administered to pediatric/YA patients with rel AML after allo-HCT. Correlative immunology discovered that ML NK cells within NRs express higher TIGIT, NKG2A, and CD8a. The persistence of eML NK cells at day 28 was associated with achieving a CR. These data support ongoing clinical investigation of ML NK cells in pediatric/YA AML, and reveal translational strategies to further improve patient outcomes.
DISCLOSURES
Emily K Phillips, MD: No relevant conflicts of interest to declare.